Search

Your search keyword '"Garcia-Pavia P"' showing total 461 results

Search Constraints

Start Over You searched for: Author "Garcia-Pavia P" Remove constraint Author: "Garcia-Pavia P"
461 results on '"Garcia-Pavia P"'

Search Results

1. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS.

2. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.

4. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

5. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis

6. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey

7. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

8. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

9. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

10. Case report: Alternative approach for management of refractory volume overload in heart failure: usefulness of venous leg compression

12. Non-invasive assessment of HFpEF in mouse models: current gaps and future directions

15. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

17. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy

18. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor

19. Role of Early Assesment of Diuresis and Natriuresis in Detecting In-Hospital Diuretic Resistance in Acute Heart Failure

21. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy.

23. Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or Steinert's disease

24. Guía clínica para el diagnóstico y seguimiento de la distrofia miotónica tipo 1, DM1 o enfermedad de Steinert

25. X-linked Emery-Dreifuss muscular dystrophy is associated with a high risk of malignant ventricular arrhythmia

26. Genetic and phenotypic characterization of Nexilin (NEXN) related cardiomyopathy

27. Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks

32. A comprehensive CMR analysis improves risk stratification in left ventricular noncompaction

33. Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies.

35. Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy

36. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

37. Negative screening of Fabry disease in patients with conduction disorders requiring a pacemaker

38. Saw-Tooth Cardiomyopathy

39. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

40. POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas

41. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial

42. Intermediate-effect size p.Arg637Gln in FHOD3increases risk of HCM and is associated with an aggressive phenotype in homozygous carriers

43. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

44. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study

45. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy

47. HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis

50. Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry

Catalog

Books, media, physical & digital resources